Enzene Biosciences Reports the Launch of Ranibizumab Biosimilar for the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
Shots:
- Enzene Biosciences launches Accentrix (biosimilar Lucentis), across India for the treatment of patients with neovascular AMD
- Accentrix has depicted a comparative clinical efficacy to Lucentis in a P-III trial. The biosimilar demonstrated comparable product purity and binding and inhibition of VEGF-A, effectively interrupting its interaction with its receptors
- Enzene developed Accentrix using its “state of the art MAR system” in Chakan plant (Pune, India). Additionally, Enzene is currently developing three biosimilars in across stages with plans to expand footprint in the US
Ref: Ophthalmology | Image: Enzene Biosciences
Related News:- Lupin and Amman Pharma Signs an Exclusive Agreement for Licensing and Supply of Ranibizumab (Biosimilar, Lucentis)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
